Dr Reddys Laboratories Ltd Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
N/A
Margin
N/A
Fundraise
N/A
Order
N/A
Capex
N/A
0 of 0 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
See what Dr Reddys Laboratories Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Dr Reddys Laboratories Ltd management said on order book — free account, 30 seconds.
Capex plans
Track Dr Reddys Laboratories Ltd — get its next earnings analysis in your feed
How does Dr Reddys Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Dr Reddys Laboratories Ltd rank in Pharmaceuticals & Biotechnology?
Compare Dr Reddys Laboratories Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Dr Reddys Laboratories Ltd's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q2 FY27)
4,979 crores, up 51% YoY (Page 23). Key results statement takeaways from Torrent Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sect
- Sakar Healthcare Ltd (Q2 FY27)
2,985.57 lakh (approximately 51.9% growth) . Key results statement takeaways from Sakar Healthcare Ltd's Q2 FY27 results statement — and how it ranks against se
- Beta Drugs Ltd (Q2 FY27)
H1 FY25: ₹180 Crs . Key investor presentation takeaways from Beta Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- Bajaj Healthcare Ltd (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj